FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3096388633> ?p ?o ?g. }

• W3096388633 endingPage "100115" @default.
• W3096388633 startingPage "100115" @default.
• W3096388633 abstract "Hyperprogressive disease (HPD) as a consequence of immune checkpoint inhibitors in NSCLC has been reported in multiple studies. However, inconsistent results in incidence and survival outcomes within studies, together with different assessment methods, have led to increasing controversy regarding the concept of HPD.Consecutive patients treated with nivolumab (N = 42) or docetaxel (N = 37) were evaluated. HPD was quantified by applying three different methods (tumor growth rate [TGR], tumor growth kinetics [TGK], and Response Evaluation Criteria in Solid Tumors version 1.1 [RECIST 1.1]). HPD rates were compared between and within both cohorts using the different methods.Using TGR, TGK, and RECIST 1.1, we identified seven (16.7%), seven (16.7%), and six (14.3%) patients with HPD in the nivolumab cohort and three (8.1%), four (10.8%), and five (13.6%) in the docetaxel cohort, respectively. We observed a higher concordance between TGR and TGK (90.1%) compared with RECIST 1.1 (31.3% and 37.5% with TGR and TGK, respectively). We found no significant differences in the overall survival between patients with progressive disease and HPD in either cohort.TGR and TGK revealed high concordance rates for identifying patients with HPD in NSCLC. The incidence of HPD was numerically higher in patients treated with immune checkpoint inhibitors. Standardization of methods for measuring HPD and its exploration in larger studies are needed to establish its clinical meaning in NSCLC." @default.
• W3096388633 created "2020-11-09" @default.
• W3096388633 creator A5000601939 @default.
• W3096388633 creator A5008993020 @default.
• W3096388633 creator A5011117439 @default.
• W3096388633 creator A5012688499 @default.
• W3096388633 creator A5013421605 @default.
• W3096388633 creator A5016253932 @default.
• W3096388633 creator A5034441516 @default.
• W3096388633 creator A5038648114 @default.
• W3096388633 creator A5046949797 @default.
• W3096388633 creator A5048381163 @default.
• W3096388633 creator A5060996400 @default.
• W3096388633 creator A5065677035 @default.
• W3096388633 creator A5079327883 @default.
• W3096388633 date "2021-01-01" @default.
• W3096388633 modified "2023-10-16" @default.
• W3096388633 title "Comparison of Different Methods for Defining Hyperprogressive Disease in NSCLC" @default.
• W3096388633 cites W2019607817 @default.
• W3096388633 cites W2102673471 @default.
• W3096388633 cites W2104347254 @default.
• W3096388633 cites W2156353875 @default.
• W3096388633 cites W2296049142 @default.
• W3096388633 cites W2554618897 @default.
• W3096388633 cites W2572174216 @default.
• W3096388633 cites W2601621622 @default.
• W3096388633 cites W2605497049 @default.
• W3096388633 cites W2891266481 @default.
• W3096388633 cites W2898126801 @default.
• W3096388633 cites W2909887958 @default.
• W3096388633 cites W2935797142 @default.
• W3096388633 cites W2991361825 @default.
• W3096388633 cites W3005152261 @default.
• W3096388633 cites W3033353648 @default.
• W3096388633 doi "https://doi.org/10.1016/j.jtocrr.2020.100115" @default.
• W3096388633 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8474364" @default.
• W3096388633 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34589976" @default.
• W3096388633 hasPublicationYear "2021" @default.
• W3096388633 type Work @default.
• W3096388633 sameAs 3096388633 @default.
• W3096388633 citedByCount "2" @default.
• W3096388633 countsByYear W30963886332022 @default.
• W3096388633 crossrefType "journal-article" @default.
• W3096388633 hasAuthorship W3096388633A5000601939 @default.
• W3096388633 hasAuthorship W3096388633A5008993020 @default.
• W3096388633 hasAuthorship W3096388633A5011117439 @default.
• W3096388633 hasAuthorship W3096388633A5012688499 @default.
• W3096388633 hasAuthorship W3096388633A5013421605 @default.
• W3096388633 hasAuthorship W3096388633A5016253932 @default.
• W3096388633 hasAuthorship W3096388633A5034441516 @default.
• W3096388633 hasAuthorship W3096388633A5038648114 @default.
• W3096388633 hasAuthorship W3096388633A5046949797 @default.
• W3096388633 hasAuthorship W3096388633A5048381163 @default.
• W3096388633 hasAuthorship W3096388633A5060996400 @default.
• W3096388633 hasAuthorship W3096388633A5065677035 @default.
• W3096388633 hasAuthorship W3096388633A5079327883 @default.
• W3096388633 hasBestOaLocation W30963886331 @default.
• W3096388633 hasConcept C121608353 @default.
• W3096388633 hasConcept C126322002 @default.
• W3096388633 hasConcept C143998085 @default.
• W3096388633 hasConcept C160798450 @default.
• W3096388633 hasConcept C2524010 @default.
• W3096388633 hasConcept C2776694085 @default.
• W3096388633 hasConcept C2777701055 @default.
• W3096388633 hasConcept C2778822529 @default.
• W3096388633 hasConcept C2779134260 @default.
• W3096388633 hasConcept C2779984678 @default.
• W3096388633 hasConcept C2780030458 @default.
• W3096388633 hasConcept C2781190966 @default.
• W3096388633 hasConcept C2989005 @default.
• W3096388633 hasConcept C33923547 @default.
• W3096388633 hasConcept C61511704 @default.
• W3096388633 hasConcept C71924100 @default.
• W3096388633 hasConcept C72563966 @default.
• W3096388633 hasConceptScore W3096388633C121608353 @default.
• W3096388633 hasConceptScore W3096388633C126322002 @default.
• W3096388633 hasConceptScore W3096388633C143998085 @default.
• W3096388633 hasConceptScore W3096388633C160798450 @default.
• W3096388633 hasConceptScore W3096388633C2524010 @default.
• W3096388633 hasConceptScore W3096388633C2776694085 @default.
• W3096388633 hasConceptScore W3096388633C2777701055 @default.
• W3096388633 hasConceptScore W3096388633C2778822529 @default.
• W3096388633 hasConceptScore W3096388633C2779134260 @default.
• W3096388633 hasConceptScore W3096388633C2779984678 @default.
• W3096388633 hasConceptScore W3096388633C2780030458 @default.
• W3096388633 hasConceptScore W3096388633C2781190966 @default.
• W3096388633 hasConceptScore W3096388633C2989005 @default.
• W3096388633 hasConceptScore W3096388633C33923547 @default.
• W3096388633 hasConceptScore W3096388633C61511704 @default.
• W3096388633 hasConceptScore W3096388633C71924100 @default.
• W3096388633 hasConceptScore W3096388633C72563966 @default.
• W3096388633 hasFunder F4320307115 @default.
• W3096388633 hasFunder F4320307765 @default.
• W3096388633 hasFunder F4320307779 @default.
• W3096388633 hasFunder F4320310441 @default.
• W3096388633 hasFunder F4320321595 @default.
• W3096388633 hasFunder F4320332932 @default.
• W3096388633 hasFunder F4320334923 @default.

• next